fashion -WSS

fashion

author：knowledge 2025-09-28 15:20:57 - browse：28

Apellis Pharmaceuticals said Tuesday that it had identified “internal structural variations” in a type of needle used by doctors to prepare syringes of its eye disease drug Syfovre as a possible cause of severe eye inflammation reported in patients receiving the treatment — but the company stopped short of definitively linking the needle to the cases.

Additionally, Apellis confirmed one additional case of the severe and potentially blinding side effect, known as retinal occlusive vasculitis, or ROV, that occurred in May. But with thousands of more Syfovre eye injections also performed, the overall frequency of ROV remains unchanged and rare, even with the added scrutiny and increased physician monitoring.

Apellis shares rose 30% to $40 in Wednesday’s pre-market trading on the growing belief amongst investors that Syfovre’s safety crisis is abating.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Dewpoint Therapeutics lays off staff after losing partnerships

WSS

Achieving telehealth equity for people with hearing loss

Achieving telehealth equity for people with hearing loss

Readout Newsletter: Merck, J&J, and long Covid

Research misconduct: Proposed new rules face resistance

New research sheds light on how often breast cancer is overdiagnosed

Why doctors need education on FDA device approval process

explore

fashion

focus

Activists slam private health insurers over coverage restrictions

Bubonic plague hit France in 1720. Officials dithered. Sound familiar?

Cancer drug shortages should be causing more outrage

How digital therapeutics firms are pivoting after Pear's bankruptcy

How one medical school became remarkably diverse

Guardant Health colon cancer test endorsed by FDA advisory panel

Guidelines to prevent youth baseball injuries need more muscle

FDA clears AI tool for detecting skin cancer

Walensky prepares to leave CDC — and Congress — behind

Eli Lilly, Pfizer, and others want in on the online prescription market

knowledge

Guardant Health colon cancer test endorsed by FDA advisory panel

The world needs the new pandemic treaty

Asahi Kasei to buy Calliditas, picking up kidney disease drug

Dewpoint Therapeutics lays off staff after losing partnerships

FDA clears AI tool for detecting skin cancer

Medical students need to learn the potent medicine of empathy

knowledge

Wikipedia

knowledge

Wikipedia